Investment
Features
FeesSafety
Academy
More
Pluang+

Western Star identifies two strong tungsten soil anomalies at Rowland Property, advancing drill targets in Nevada.

Market News
18 Sep 2026
TheNewswire
View Source
Bullish
Western Star identifies two strong tungsten soil anomalies at Rowland Property, advancing drill targets in Nevada.

Western Star Resources announced results from its Phase 2 soil survey at the Rowland Tungsten Property in Nevada, revealing two distinct tungsten-in-soil anomalies. The Rowland Main anomaly includes a high-grade sample with 0.53% WO₃, located 250 meters from historical workings on previously untested ground, while the Northern Zone B anomaly shows significant tungsten values within a modeled intrusive body. These findings refine drill targets and will be integrated with geophysical data and previous assays to guide further exploration. Additional soil results from the nearby White Star Tungsten Project are pending.

The Rowland Tungsten Property's Phase 2 soil survey revealed a high-grade 0.53% WO3 sample. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 18, 2026 17:42 WIB: out of 33 priced US stocks, 24 rose and 9 fell. Notable movers include Kinross Gold Corporation (KGC) at USD 28.92 with a 1-day change of +1.56% and 99% buy order activity, MP Materials (MP) at USD 50.14 with +1.54% and 83% buy order activity, and Agnico Eagle Mines Ltd (AEM) at USD 204.27 with +1.44% and 100% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin surges past $80K as $183M in short bets liquidate, fueling a sharp price rally.

Bitcoin's price surged from around $76,400 to nearly $81,000 on September 18, 2026, driven by a rapid liquidation of $192 million in leveraged crypto positions, including $183 million in short bets. This forced buying pushed Bitcoin above $80,000 for...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App